drugset / Trial / NCT01929746
Daclizumab Japanese PK Study
RandomizedParallel-groupSingle-blindTreatment
Summary
The primary objective of the study is to evaluate the pharmacokinetic (PK) profile of BIIB019 (Daclizumab High Yield Process; DAC HYP) administered as a single subcutaneous (SC) dose (75 mg or 150 mg) Japanese and Caucasian adult healthy volunteers. The secondary objective of this study in this study population is to assess the safety and tolerability of BIIB019 administered as a single SC dose (75 mg or 150 mg).
Timeline
- Start
- 2013-10
- Primary completion
- 2014-03
- Completion
- 2014-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BIIB019 | Unknown | 75 mg | Subcutaneous |
| Subject | BIIB019 | Unknown | 150 mg | Subcutaneous |
Indications
No indication recorded.